Skip to main
ACOG

ACOG Stock Forecast & Price Target

ACOG Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Cognition is expected to have potential revenue of $540 million in the US, leading to a total enterprise value of $520 million. The acquisition of Galantos Pharma GmbH i.L. in early settlement provides for a simplified and streamlined royalty agreement and the company is sufficiently funded to reach profitability in the near- and medium-term. Risks include delayed market uptake and clinical setbacks, but we maintain our Buy rating and a 12-month price target of $18 based on continued commercial and financial progress.

Bears say

Alpha Cognition is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases with their current focus on commercializing ZUNVEYL, a differentiated treatment for Alzheimers disease. However, their financials may be hindered by the limited market for such treatments and the potential for cheaper generic alternatives. The company is making strides in clinical trials and expanding its evidence base, but the new appointment of a director with experience in successful company sales may indicate potential difficulties in achieving financial success.

ACOG has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Cognition Inc (ACOG) Forecast

Analysts have given ACOG a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACOG has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Cognition Inc (ACOG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.